Login / Signup

Semaglutide is effective in type 2 diabetes and obesity with schizophrenia.

Kaoru NodaTakehiro KatoNao NomuraMayu SakaiSodai KubotaTokuyuki HiroseYanyan LiuYoshihiro TakahashiKen TakaoMasami MizunoTakuo HirotaTetsuya SuwaYukio HorikawaDaisuke Yabe
Published in: Diabetology international (2022)
The GLP-1 receptor agonist semaglutide can be effective in maintaining appropriate control of glycemia and body weight in diabetes and obesity with schizophrenia.
Keyphrases
  • type diabetes
  • body weight
  • insulin resistance
  • bipolar disorder
  • glycemic control
  • metabolic syndrome
  • weight loss
  • cardiovascular disease
  • high fat diet induced
  • weight gain
  • adipose tissue
  • skeletal muscle